WO2006110745A3 - Anticorps anti-psma conjugues - Google Patents

Anticorps anti-psma conjugues Download PDF

Info

Publication number
WO2006110745A3
WO2006110745A3 PCT/US2006/013473 US2006013473W WO2006110745A3 WO 2006110745 A3 WO2006110745 A3 WO 2006110745A3 US 2006013473 W US2006013473 W US 2006013473W WO 2006110745 A3 WO2006110745 A3 WO 2006110745A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
conjugated anti
psma antibodies
conjugated
antibodies
Prior art date
Application number
PCT/US2006/013473
Other languages
English (en)
Other versions
WO2006110745A2 (fr
Inventor
John L Tedesco
Original Assignee
Cytogen Corp
John L Tedesco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp, John L Tedesco filed Critical Cytogen Corp
Priority to JP2008505645A priority Critical patent/JP2008535865A/ja
Priority to CA002603847A priority patent/CA2603847A1/fr
Priority to EP06749755A priority patent/EP1871810A2/fr
Priority to AU2006235421A priority patent/AU2006235421A1/en
Publication of WO2006110745A2 publication Critical patent/WO2006110745A2/fr
Publication of WO2006110745A3 publication Critical patent/WO2006110745A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles compositions, des méthodes de traitement du cancer, des méthodes de diagnostic du cancer, des compositions pharmaceutiques et des méthodes pour fabriquer des anticorps conjugués comprenant un anticorps qui se lie immunospécifiquement à l'antigène de la membrane spécifique à la prostate et est conjugué à un radio-isotope par une liaison MeO-DOTA.
PCT/US2006/013473 2005-04-08 2006-04-10 Anticorps anti-psma conjugues WO2006110745A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008505645A JP2008535865A (ja) 2005-04-08 2006-04-10 抗ｐｓｍａコンジュゲート抗体
CA002603847A CA2603847A1 (fr) 2005-04-08 2006-04-10 Anticorps anti-psma conjugues
EP06749755A EP1871810A2 (fr) 2005-04-08 2006-04-10 Anticorps anti-psma conjugués
AU2006235421A AU2006235421A1 (en) 2005-04-08 2006-04-10 Conjugated anti-PSMA antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66934705P 2005-04-08 2005-04-08
US60/669,347 2005-04-08

Publications (2)

Publication Number Publication Date
WO2006110745A2 WO2006110745A2 (fr) 2006-10-19
WO2006110745A3 true WO2006110745A3 (fr) 2007-07-26

Family

ID=37087639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013473 WO2006110745A2 (fr) 2005-04-08 2006-04-10 Anticorps anti-psma conjugues

Country Status (5)

Country Link
EP (1) EP1871810A2 (fr)
JP (1) JP2008535865A (fr)
AU (1) AU2006235421A1 (fr)
CA (1) CA2603847A1 (fr)
WO (1) WO2006110745A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (fr) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Anticorps et multimeres de proteines psma
EP1726650A1 (fr) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Anticorps monoclonaux et fragments d'anticorps monocaténaires contre l'antigène spécifique de surface membranaire de la prostate
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
AU2007343600B2 (en) * 2007-01-11 2012-06-28 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
DK2326350T3 (da) 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3256495A4 (fr) * 2015-02-11 2018-09-19 Aptevo Research and Development LLC Compositions et méthodes de polythérapie combinées à des protéines se liant à l'antigène membranaire spécifique de la prostate
AU2017368005A1 (en) 2016-11-30 2019-06-20 Cornell University Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
EP3571221A2 (fr) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
WO2018187791A1 (fr) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Cellules génétiquement modifiées exprimant un antigène membranaire spécifique de la prostate (psma) ou une forme modifiée de celui-ci et procédés associés

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US6875886B2 (en) * 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
US20050175541A1 (en) * 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
US20050249671A9 (en) * 2002-12-23 2005-11-10 David Parmelee Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875886B2 (en) * 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20050249671A9 (en) * 2002-12-23 2005-11-10 David Parmelee Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
US20050175541A1 (en) * 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOHSIN H. ET AL.: "Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu", BIOCONG. CHEM., vol. 17, no. 2, March 2006 (2006-03-01) - April 2006 (2006-04-01), pages 485 - 492, XP003015907 *
YORDANOV A.T. ET AL.: "Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and a cyclic ligands", NUCL. MED. BIOL., vol. 34, no. 2, February 2007 (2007-02-01), pages 173 - 183, XP005890918 *

Also Published As

Publication number Publication date
AU2006235421A1 (en) 2006-10-19
JP2008535865A (ja) 2008-09-04
CA2603847A1 (fr) 2006-10-19
EP1871810A2 (fr) 2008-01-02
WO2006110745A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006110745A3 (fr) Anticorps anti-psma conjugues
WO2006084226A3 (fr) Anticorps se liant a epha2 et procedes d'utilisation de ceux-ci
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
EP2570137A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (DEC-205)
WO2006102395A3 (fr) Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
WO2007109321A3 (fr) Anticorps modifiés dirigés contre l'antigène de cellules souches prostatiques servant à cibler le cancer
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2009130575A3 (fr) Anticorps monoclonal isolé ou fragment de celui-ci se liant à l'antigène membranaire spécifique de la prostate, ses conjugués et utilisations
WO2008066691A3 (fr) Tes7, et anticorps se liant à celui-ci
WO2005117986A3 (fr) Conjugues de medicaments anticorps et procedes correspondants
WO2007100385A3 (fr) Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées
WO2006084075A3 (fr) Modulateurs adam-9
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
WO2006084092A3 (fr) Anticorps de recepteur de l'oncostatine m
WO2008053330A3 (fr) Anticorps monoclonaux et fragments de ceux-ci dirigés contre le récepteur de type ii de l'hormone antimüllérienne humaine (amhr-ii)
WO2007109376A3 (fr) Thérapeutique anticorps antigène de cellules anti-tumorales
WO2006084078A3 (fr) Antigene jam-3 et anticorps se liant a celui-ci
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2005121179A3 (fr) Anticorps vis-a-vis du recepteur de transferine
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
WO2008036449A3 (fr) Anticorps chimiques destinés à l'immunothérapie et à l'imagerie
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
WO2006083852A3 (fr) Luca2 et anticorps s'y liant
WO2006076584A3 (fr) Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci
WO2008098917A3 (fr) Nouveaux anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2603847

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008505645

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006235421

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006749755

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006235421

Country of ref document: AU

Date of ref document: 20060410

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU